- Home
- CVR vs XCUR Comparison
CVR vs XCUR Comparison
Compare CVR & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | XCUR |
|---|---|---|
| Founded | 1920 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.2M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CVR | XCUR |
|---|---|---|
| Price | $10.87 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 22.1K |
| Earning Date | 11-06-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,890,260.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $8.50 | $1.05 |
| 52 Week High | $15.00 | $9.48 |
Technical Indicators
Market Signals| Indicator | CVR | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 40.95 |
| Support Level | $9.42 | $1.05 |
| Resistance Level | $10.99 | $1.48 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 89.61 | 21.77 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.